Induction of interleukin 1 by synthetic and naturally occurring muramyl peptides. 1986

C A Dinarello, and J M Krueger

Like bacterial lipopolysaccharides (endotoxins), synthetic muramyl peptides (MPs) are thought to exert many of their biological effects by inducing the production of various mediators from host cells. Both synthetic muramyl dipeptide (MDP) and naturally occurring sleep factor (SF), which contains an MP structure, stimulate human monocytes to produce interleukin 1 (IL 1). IL 1 is a family of unique polypeptides that mediate a variety of host defense functions and possess several biological properties, many of which are shared with MPs. Endotoxins are potent inducers of IL 1, but polymyxin B, which blocks endotoxin's biological activities, has no effect on MP-induced IL 1 production. SF purified from human urine and SF isolated from the peritoneal fluid of patients undergoing chronic ambulatory peritoneal dialysis (CAPD) induce IL 1 when incubated with human mononuclear cells in vitro. SF from urine or CAPD fluid induces IL 1 production in the picrogram per milliliter range whereas synthetic MDP requires microgram per milliliter concentrations. Thus, both synthetic and naturally occurring MPs exert their biological effects, in part, by inducing IL 1.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D011112 Polymyxin B A mixture of polymyxins B1 and B2, obtained from BACILLUS POLYMYXA strains. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for treatment of infections with gram-negative bacteria, but may be neurotoxic and nephrotoxic. Aerosporin,Polymyxin B Sulfate
D004731 Endotoxins Toxins closely associated with the living cytoplasm or cell wall of certain microorganisms, which do not readily diffuse into the culture medium, but are released upon lysis of the cells. Endotoxin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000119 Acetylmuramyl-Alanyl-Isoglutamine Peptidoglycan immunoadjuvant originally isolated from bacterial cell wall fragments; also acts as pyrogen and may cause arthritis; stimulates both humoral and cellular immunity. Mur-NAc-L-Ala-D-isoGln,Muramyl Dipeptide,Acetylmuramyl Alanyl Isoglutamine,N-Acetyl-Muramyl-L-Alanyl-D-Glutamic-alpha-Amide,N-Acetylmuramyl-L-Alanyl-D-Isoglutamine,Alanyl Isoglutamine, Acetylmuramyl,Dipeptide, Muramyl,Isoglutamine, Acetylmuramyl Alanyl,Mur NAc L Ala D isoGln,N Acetyl Muramyl L Alanyl D Glutamic alpha Amide,N Acetylmuramyl L Alanyl D Isoglutamine

Related Publications

C A Dinarello, and J M Krueger
July 2021, Journal of peptide science : an official publication of the European Peptide Society,
C A Dinarello, and J M Krueger
October 1982, Science (New York, N.Y.),
C A Dinarello, and J M Krueger
November 1979, Biochemical pharmacology,
C A Dinarello, and J M Krueger
January 2009, Current pharmaceutical design,
C A Dinarello, and J M Krueger
January 1953, Advances in protein chemistry,
C A Dinarello, and J M Krueger
January 1966, Advances in protein chemistry,
C A Dinarello, and J M Krueger
November 1975, Toxicon : official journal of the International Society on Toxinology,
C A Dinarello, and J M Krueger
January 1990, Basic life sciences,
C A Dinarello, and J M Krueger
August 1994, Journal of interferon research,
Copied contents to your clipboard!